We are thrilled to be included in the BioSpace NextGen Class of 2025! This list of 25 companies represents the editors' picks for "the hottest new life sciences companies in the United States" launched between October 1, 2023, and September 30, 2024. https://lnkd.in/e838FJrV
关于我们
Red Queen Therapeutics is a clinical-stage company working to deliver important and accessible new treatment options for a broad range of virus-borne illnesses including influenzas, coronaviruses, and other current and emerging pathogens. Co-founded by Apple Tree Partners (ATP) and biomedical researcher Loren Walensky, M.D., Ph.D., Red Queen is applying its proprietary stapled lipopeptide technology to develop and deliver new treatments for a broad range of viruses, including coronaviruses, influenzas, and other enveloped viruses. The Red Queen platform mechanism of action, fusion inhibition, is a mode of early intervention that can prevent or mitigate viral infection, enabling accelerated viral clearance and avoidance of severe disease. Because Red Queen therapies target the highly conserved mechanism of viral fusion, they can be used across entire viral families and their variants. And because Red Queen’s agents do not depend upon immune system activation, they offer instantaneous protection and are particularly suitable for use by immunocompromised people. Red Queen’s stapled lipopeptide therapeutics are designed to be shelf-stable at room temperature and can be formulated and delivered in multiple ways, including topically by nasal spray or inhaler, or systematically by injection.
- 网站
-
www.redqueentx.com
Red Queen Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boston，MA
- 类型
- 私人持股
- 领域
- antivirals、biotechnology和pharmaceuticals
地点
-
主要
获取路线
US，MA，Boston
Red Queen Therapeutics员工
动态
-
We're excited about momentum on multiple fronts here at Red Queen, including expansion of our licensing agreement with Dana-Farber Cancer Institute and progress in our pan-influenza program. https://lnkd.in/eeUH34WB
-
Read about our latest progress in the Fall 2024 newsletter from the Innovations Office at Dana-Farber Cancer Institute! https://lnkd.in/ebGMcxfE
-
From the Centers for Disease Control and Prevention, another cautionary study, this one showing a relatively high prevalence of past #H5N1 infection among dairy workers. Aside from the?implications for our efforts to develop strategies against H5NI itself, this argues for taking aggressive and proactive measures to minimize coinfections among dairy workers. https://lnkd.in/euZtGKyf
-
Our collaboration with BARDA has been an important accelerator of our pan-influenza antiviral program, RQ-03, and their support echoes what we are hearing from our industry and venture peers. Versatility, broad coverage, and lack of toxicity and drug-drug interactions are the main drivers of enthusiasm for our platform. We greatly appreciate the support from BARDA and the tremendous efforts of our Red Queen team! https://lnkd.in/gevBRQP6
-
H5N1 has now been seen in swine for the first time in the U.S.?While there is no immediate threat of widespread human disease, this detection of H5N1 in pigs – well known mixing vessels for influenza viruses – is concerning.?At Red Queen, we are advancing our preclinical pan-flu candidate and significant activity against H5N1 remains a top priority for us. https://lnkd.in/eTZRAJfN
-
Check out the story in BioCentury Inc. by Richard Guy, PhD profiling our company, our scientific platform, and our efforts to deliver new antivirals. https://lnkd.in/e7Z_sC2q
-
-
Thanks to Rowan Walrath for her expert reporting in this feature story in American Chemical Society's Chemical & Engineering News.
Around 3 years ago, Dana-Farber Cancer Institute scientist Loren Walensky approached the venture firm ATP (Apple Tree Partners) with an idea. He and his team had found a way to use chemically stapled lipopeptides to block the virus SARS-CoV-2, and they believed the same technology could be used for other enveloped viruses, such as respiratory syncytial virus, Ebola virus, and Nipah virus. ATP set to work testing that theory and quietly built a company around it. Now that start-up is emerging from stealth.?Red Queen Therapeutics?launched Tuesday with $55 million in venture backing, a contract with the Biomedical Advanced Research and Development Authority (BARDA), and a pipeline led by a drug candidate that has already been tested in humans. Most antivirals work by stopping a virus from replicating.?Paxlovid, for instance, blocks an enzyme that SARS-CoV-2 uses to make copies of itself. In contrast, the peptide made by Walensky’s team is designed to prevent a virus from infecting a cell at all. As CEO Mark Mitchnick puts it, an enveloped virus will typically park itself on a cell membrane, find a receptor it likes, and then bring itself closer to the membrane so it fuses. That fusion process involves the folding of two helical protein structures belonging to the virus, usually the heptad repeat 1 and 2 domain α-helices (called HR1 and HR2). “It literally jackknives and brings the virus closer to the body of the protein where the fusion takes place,” Mitchnick says. Red Queen’s peptide is designed to stop that folding process from happening. “We mimic the part of HR2 that binds to HR1 . . . so HR2 cannot fold onto HR1,” Mitchnick says. “It’s literally a wrench in the works.” More in my latest for C&EN: https://lnkd.in/eX-eUYas
-
Thanks to Frank Vinluan and MedCity News for the very informative writeup of our company and its platform. https://lnkd.in/g-jkxcHH
-
Today we are thrilled to formally "unstealth." With $55M in Series A funding from ATP (Apple Tree Partners), clinical proof-of-concept for our novel antiviral platform, and a terrific team, we are excited about continuing our progress on behalf of patients! https://lnkd.in/ek5dGznq